Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05634499 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer

Study acronym: EndomERA
StatusCompleted
PhasePhase 2
Started2023-06-27
View on ClinicalTrials.gov ↗
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.

Amendment history 4 changes detected by DataLookout

2026-09-15
Trial completed
2026-09-15
Final enrollment: 33 participants (planned 30)
2026-04-14
Primary completion pushed: 2026-06-30 → 2026-08-28
2026-04-14
Completion pushed: 2026-06-30 → 2026-08-28
Trial Details
NCT Number NCT05634499
Lead Sponsor Hoffmann-La Roche
Conditions Endometrial Cancer
Enrollment 33 participants
Start Date 2023-06-27
Primary Completion 2026-08-25 (estimated)
Study Completion 2026-08-25 (estimated)
Updated on ClinicalTrials.gov 2026-09-14